monotherapy

Early prevention of myeloma: dara for high-risk MGUS and low-risk SMM

MRD assessment in the era of novel therapies for CLL

Single agent ibrutinib produces long-term disease control in Waldenström’s: the pivotal trial

Ibrutinib for the treatment of Bing-Neel syndrome

Zanubrutinib in mantle cell lymphoma: updated safety and efficacy data

CLL12: ibrutinib monotherapy upfront, a potential competitor for ‘watch-and-wait’?

Current affairs: opinion on quizartinib approval status in AML

RADIUS results: midostaurin reduces relapse after ASCT in FLT3-ITD AML

Duvelisib after progression on ofatumumab in R/R CLL: DUO crossover extension study

7-year follow-up of ibrutinib monotherapy for R/R and first-line CLL

Beat AML: promising results with enasidenib for AML in the frontline

Venetoclax monotherapy for relapsed/refractory Waldenström’s macroglobulinemia

Long-term follow-up of acalabrutinib in R/R mantle cell lymphoma

A big year for CLL: ibrutinib updates from ASH

Stapled peptide ALRN-6924 for AML and MDS

Achieving longer remissions with venetoclax monotherapy in R/R CLL